Does the media favor ALLO or ALEC?

In the previous week, Alector had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for Alector and 3 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.19 beat Alector's score of 0.11 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CADL or ALEC?

In the previous week, Candel Therapeutics and Candel Therapeutics both had 4 articles in the media. Candel Therapeutics' average media sentiment score of 1.03 beat Alector's score of 0.11 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALEC or AURA more profitable?

Aura Biosciences has a net margin of 0.00% compared to Alector's net margin of -680.83%. Aura Biosciences' return on equity of -78.12% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -680.83% -295.17% -40.95% Aura Biosciences N/A -78.12% -64.08%

Does the media favor ALEC or AURA?

In the previous week, Alector had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Alector and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Alector's score of 0.11 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNPR or ALEC?

In the previous week, Alector had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for Alector and 3 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.46 beat Alector's score of 0.11 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alector (ALEC) Competitors

$1.46 -0.06 (-3.64%)

As of 02:50 PM Eastern

Compare

ALEC vs. ALLO, CADL, AURA, MNPR, and RLMD

Should you buy Alector stock or one of its competitors? MarketBeat compares Alector with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alector include Allogene Therapeutics (ALLO), Candel Therapeutics (CADL), Aura Biosciences (AURA), Monopar Therapeutics (MNPR), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.

How does Alector compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Allogene Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Allogene Therapeutics' return on equity of -56.45% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Alector	-680.83%	-295.17%	-40.95%

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Alector has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Allogene Therapeutics currently has a consensus price target of $8.52, indicating a potential upside of 356.96%. Alector has a consensus price target of $3.63, indicating a potential upside of 149.14%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Alector has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	32,185.24	-$190.89M	-$0.77	N/A
Alector	$21.05M	7.67	-$142.93M	-$1.19	N/A

In the previous week, Alector had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for Alector and 3 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.19 beat Alector's score of 0.11 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Allogene Therapeutics beats Alector on 11 of the 17 factors compared between the two stocks.

How does Alector compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Candel Therapeutics has a beta of -0.52, suggesting that its share price is 152% less volatile than the broader market. Comparatively, Alector has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Candel Therapeutics has higher earnings, but lower revenue than Alector. Candel Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Alector	$21.05M	7.67	-$142.93M	-$1.19	N/A

In the previous week, Candel Therapeutics and Candel Therapeutics both had 4 articles in the media. Candel Therapeutics' average media sentiment score of 1.03 beat Alector's score of 0.11 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Candel Therapeutics' return on equity of -60.42% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Alector	-680.83%	-295.17%	-40.95%

Candel Therapeutics presently has a consensus price target of $18.57, suggesting a potential upside of 85.25%. Alector has a consensus price target of $3.63, suggesting a potential upside of 149.14%. Given Alector's higher probable upside, analysts plainly believe Alector is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Candel Therapeutics beats Alector on 8 of the 14 factors compared between the two stocks.

How does Alector compare to Aura Biosciences?

Alector (NASDAQ:ALEC) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Aura Biosciences has lower revenue, but higher earnings than Alector. Aura Biosciences is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	7.67	-$142.93M	-$1.19	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Aura Biosciences has a net margin of 0.00% compared to Alector's net margin of -680.83%. Aura Biosciences' return on equity of -78.12% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Aura Biosciences	N/A	-78.12%	-64.08%

Alector currently has a consensus price target of $3.63, indicating a potential upside of 149.14%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 189.55%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

85.8% of Alector shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alector has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

In the previous week, Alector had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Alector and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Alector's score of 0.11 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alector beats Aura Biosciences on 8 of the 15 factors compared between the two stocks.

How does Alector compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Monopar Therapeutics has higher earnings, but lower revenue than Alector. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Alector	$21.05M	7.67	-$142.93M	-$1.19	N/A

In the previous week, Alector had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for Alector and 3 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.46 beat Alector's score of 0.11 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics presently has a consensus price target of $108.75, suggesting a potential upside of 4.70%. Alector has a consensus price target of $3.63, suggesting a potential upside of 149.14%. Given Alector's higher probable upside, analysts plainly believe Alector is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Monopar Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Monopar Therapeutics' return on equity of -12.84% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Alector	-680.83%	-295.17%	-40.95%

Monopar Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Alector has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Summary

Monopar Therapeutics beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to Relmada Therapeutics?

Alector (NASDAQ:ALEC) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Relmada Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Relmada Therapeutics' return on equity of -71.22% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Alector presently has a consensus price target of $3.63, suggesting a potential upside of 149.14%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 89.13%. Given Alector's higher possible upside, analysts plainly believe Alector is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Alector had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 4 mentions for Alector and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.44 beat Alector's score of 0.11 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alector	Neutral
Relmada Therapeutics	Neutral

Alector has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

85.8% of Alector shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Relmada Therapeutics has lower revenue, but higher earnings than Alector. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	7.67	-$142.93M	-$1.19	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Summary

Relmada Therapeutics beats Alector on 9 of the 16 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$161.11M	$3.65B	$6.75B	$12.55B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.22	21.18	26.99	24.40
Price / Sales	7.67	312.31	585.80	117.91
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	5.20	8.59	10.86	6.35
Net Income	-$142.93M	$23.83M	$3.58B	$330.89M
7 Day Performance	-24.61%	-2.91%	-1.95%	-0.87%
1 Month Performance	-4.90%	6.98%	3.47%	-0.26%
1 Year Performance	-12.87%	49.68%	26.84%	20.20%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	2.449 of 5 stars	$1.46 -3.6%	$3.63 +149.1%	-6.2%	$161.11M	$21.05M	N/A	270
ALLO Allogene Therapeutics	2.404 of 5 stars	$2.00 -4.8%	$8.52 +326.1%	+50.8%	$724.83M	$20K	N/A	310	News Coverage Positive News
CADL Candel Therapeutics	3.3384 of 5 stars	$9.49 -4.0%	$18.00 +89.7%	+65.9%	$724.64M	N/A	N/A	60	Analyst Forecast
AURA Aura Biosciences	2.1997 of 5 stars	$6.84 -2.3%	$20.50 +199.7%	+9.4%	$723.71M	N/A	N/A	50	Analyst Downgrade
MNPR Monopar Therapeutics	1.1047 of 5 stars	$106.60 +2.0%	$108.75 +2.0%	+180.3%	$700.05M	N/A	N/A	10	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors

ALEC vs. ALLO, CADL, AURA, MNPR, and RLMD

How does Alector compare to Allogene Therapeutics?

Summary

How does Alector compare to Candel Therapeutics?

Summary

How does Alector compare to Aura Biosciences?

Summary

How does Alector compare to Monopar Therapeutics?

Summary

How does Alector compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alector (ALEC) Competitors

ALEC vs. ALLO, CADL, AURA, MNPR, and RLMD

How does Alector compare to Allogene Therapeutics?

Is ALLO or ALEC more profitable?

Which has more risk and volatility, ALLO or ALEC?

Do institutionals & insiders have more ownership in ALLO or ALEC?

Do analysts rate ALLO or ALEC?

Which has better earnings and valuation, ALLO or ALEC?

Does the media favor ALLO or ALEC?

Summary

How does Alector compare to Candel Therapeutics?

Do insiders & institutionals hold more shares of CADL or ALEC?

Which has more volatility and risk, CADL or ALEC?

Which has preferable earnings & valuation, CADL or ALEC?

Does the media prefer CADL or ALEC?

Is CADL or ALEC more profitable?

Do analysts rate CADL or ALEC?

Summary

How does Alector compare to Aura Biosciences?

Which has better valuation and earnings, ALEC or AURA?

Is ALEC or AURA more profitable?

Do analysts recommend ALEC or AURA?

Do insiders & institutionals believe in ALEC or AURA?

Which has more risk and volatility, ALEC or AURA?

Does the media favor ALEC or AURA?

Summary

How does Alector compare to Monopar Therapeutics?

Which has preferable earnings & valuation, MNPR or ALEC?

Does the media favor MNPR or ALEC?

Do analysts recommend MNPR or ALEC?

Do institutionals and insiders hold more shares of MNPR or ALEC?

Is MNPR or ALEC more profitable?

Which has more volatility & risk, MNPR or ALEC?

Summary

How does Alector compare to Relmada Therapeutics?

Is ALEC or RLMD more profitable?

Do analysts prefer ALEC or RLMD?

Does the media prefer ALEC or RLMD?

Which has more volatility and risk, ALEC or RLMD?

Do insiders and institutionals hold more shares of ALEC or RLMD?

Which has preferable earnings and valuation, ALEC or RLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools